Daratumumab or Darzalex Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The daratumumab or darzalex market size has grown rapidly in recent years. It will grow from $5.61 billion in 2025 to $6.18 billion in 2026 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to approval for multiple myeloma treatment, strong clinical outcomes targeting cd38, limited alternatives in relapsed disease, oncology center adoption, increased survival rates.

The daratumumab or darzalex market size is expected to see strong growth in the next few years. It will grow to $9.02 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to expansion of combination regimens, growing multiple myeloma prevalence, increased oncology investment, development of new indications, improved patient access programs. Major trends in the forecast period include rising adoption in multiple myeloma, combination use with other oncology drugs, expansion into earlier treatment lines, hospital based monoclonal antibody therapy, growing use in hematologic malignancies.

The increasing incidence of bone marrow cancer is expected to drive the growth of the daratumumab or Darzalex market in the coming years. Bone marrow cancer includes cancers that originate in the bone marrow, such as multiple myeloma and leukemia, where abnormal blood cell production interferes with normal bodily functions. The growing incidence of bone marrow cancers is associated with factors such as an aging population, advancements in diagnostic techniques, and influences including environmental exposure, lifestyle habits, and genetic susceptibility. Daratumumab (Darzalex) is used in the treatment of multiple myeloma, a form of bone marrow cancer, by specifically targeting and eliminating abnormal plasma cells within the bone marrow. For instance, in January 2025, according to the American Cancer Society, a US-based non-profit organization, approximately 3,770 new cases of primary bone and joint cancer are expected in 2025, including 2,150 cases in men and 1,620 cases in women, along with an estimated 2,190 deaths, comprising 1,240 men and 950 women. Therefore, the rising incidence of bone marrow cancer is fueling the growth of the daratumumab or Darzalex market.

The increasing adoption of biologics and targeted therapies is expected to further propel the growth of the daratumumab or Darzalex market going forward. Targeted therapies are treatment approaches that use drugs or other agents to precisely identify and act on specific molecules involved in the growth and survival of cancer and other diseases. The uptake of biologics and targeted therapies is rising due to the growing burden of chronic diseases and advances in precision medicine, which support more personalized and effective treatment options. Daratumumab is widely used in targeted therapy because of its specific action against CD38, a protein that is highly expressed on the surface of malignant plasma cells in multiple myeloma. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, a notable increase from six approvals in 2022. As a result, the growing adoption of biologics and targeted therapies is driving the expansion of the daratumumab or Darzalex market.

Leading companies operating in the daratumumab or Darzalex market are increasingly focusing on a shift toward early-intervention oncology treatments, such as combination therapies, to improve effectiveness in managing multiple myeloma and other cancers. Combination therapies involve the use of two or more therapeutic agents with distinct mechanisms of action, often working synergistically to enhance efficacy, reduce drug resistance, and improve patient outcomes while potentially lowering adverse effects compared with single-agent treatments. For example, in July 2024, Johnson & Johnson, a US-based pharmaceutical company, received U.S. FDA approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation therapy in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant. This approval introduces a quadruplet therapy option at the time of initial diagnosis, with the potential to improve clinical outcomes for patients.

Major companies operating in the daratumumab or darzalex market are Genmab A/S, Janssen Biotech Inc.

North America was the largest region in the daratumumab or darzalex market in 2025. The regions covered in the daratumumab or darzalex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the daratumumab or darzalex market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the daratumumab market by increasing costs of imported biologic raw materials and advanced manufacturing technologies. These impacts are felt most strongly in hospital oncology settings across Europe and Asia Pacific. Higher import duties have contributed to elevated treatment costs for monoclonal antibody therapies. Distribution timelines have also been influenced by regulatory clearance processes. At the same time, tariffs are supporting localized biologics manufacturing and long term oncology drug supply stability.

The daratumumab or darzalex market research report is one of a series of new reports that provides daratumumab or darzalex market statistics, including daratumumab or darzalex industry global market size, regional shares, competitors with a daratumumab or darzalex market share, detailed daratumumab or darzalex market segments, market trends and opportunities, and any further data you may need to thrive in the daratumumab or darzalex industry. This daratumumab or darzalex market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Daratumumab, also known as Darzalex, is a monoclonal antibody medication used in the treatment of certain cancers, most notably multiple myeloma. It is engineered to specifically target and bind to CD38, a protein that is highly expressed on the surface of multiple myeloma cells, as well as on some other malignant and normal immune cells.

The main drug forms of daratumumab or Darzalex include 100 mg injection and 400 mg injection. A 100 mg injection denotes a dosage in which 100 milligrams of the active substance are administered through injection. These medications are supplied through pharmacies, hospitals, and other distribution channels and are used for a range of applications, including follicular lymphoma, mantle cell lymphoma, multiple myeloma, diffuse large B-cell lymphoma, and other related conditions.

The daratumumab or darzalex market consists of sales of darzalex faspro, darzalex injection, dexamethasone, and pomalidomide. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.